The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models

The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models

Activation of the epidermal growth factor receptor (EGFR) signaling pathway promotes the development of hepatocellular adenoma (HCA) and carcinoma (HCC). The selective EGFR inhibitor Gefitinib was found to prevent hepatocarcinogenesis in rat cirrhotic livers. Thus, Gefitinib might reduce progression...

Full description

Bibliographic Details
Main Authors: Silvia Ribback, Verena Sailer, Enrico Böhning, Julia Günther, Jaqueline Merz, Frauke Steinmüller, Kirsten Utpatel, Antonio Cigliano, Kristin Peters, Maria G. Pilo, Matthias Evert, Diego F. Calvisi, Frank Dombrowski
Format: Article
Language:English
Published: MDPI AG 2016-09-01
Series:International Journal of Molecular Sciences
Subjects:
hepatocarcinogenesis
intraportal transplantation
epidermal growth factor receptor (EGFR)
Gefitinib
Online Access:http://www.mdpi.com/1422-0067/17/10/1618

Internet

http://www.mdpi.com/1422-0067/17/10/1618

Similar Items